Submitted by MilliporeSigma
BURLINGTON, Mass., April 15, 2022 /CSRwire/ – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that its ZooMAb® recombinant antibodies platform earned Accountability, Consistency and Transparency (ACT) label from My Green Lab, a non-profit organization dedicated to creating a culture of sustainability in science.
The first-ever antibody to achieve ACT label designation, ZooMAb® antibodies received the lowest Environmental Impact Factor (EIF) scores in the chemicals and reagents category.
“Helping our customers and suppliers to reduce their impact on the environment is a key part of our sustainability strategy,” said Jeffrey Whitford, Head of Sustainability and Social Business Innovation, MilliporeSigma. “By showing how products rate in different categories, such as manufacturing; energy and water use; packaging; and end-of-life, the ACT label gives scientists another data point to help increase their sustainability. We are proud to be part of this program and are thrilled to achieve one of the top ranking EIF scores for our ZooMAb® antibodies.”
Unlike traditional monoclonal antibodies, or mAbs, made from identical immune cells from an animal-sourced parent cell, ZooMAb® antibodies use recombinant technology. This offers an endless and consistent supply, while reducing the use of animals in research.
ZooMAb® antibodies can be shipped at room temperature and then stored between 2°C and 8°C, while traditional mAbs must be shipped and stored between 2°C and 8°C, eliminating the need for specially insulated, ice-cooled containers that contribute to high packaging material consumption and transport emissions. Shipping ZooMAb ® antibodies, which weigh 2.5 g or about as heavy as a penny, at room temperature, allows for more opportunities to eventually ship the product in much smaller packaging, preventing the emission of around 175 metric tons of CO2 per year by 2025.
In addition to innovation and packaging, the following factors contributed to the low EIF score:
Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.
About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 23,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany generated sales of € 17.5 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.
More from MilliporeSigma